Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
|
Jul 2023
|
Lancet
|
myelodysplastic syndromes (MDS)
|
Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis
|
Nov 2016
|
PLoS One
|
myelodysplastic syndromes (MDS)
|
Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
|
Oct 2015
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria
|
Apr 2014
|
Pediatr Blood Cancer
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
Efficacy and safety of deferasirox in myelodysplastic syndromes
|
Feb 2013
|
Ann Hematol
|
myelodysplastic syndromes (MDS)
|
Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis
|
May 2016
|
Br J Haematol
|
myelodysplastic syndromes (MDS)
|
Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry
|
Jan 2019
|
Am J Hematol
|
aplastic anemia, paroxysmal nocturnal hemoglobinuria (PNH)
|
Effectiveness of azacitidine in higher-risk myelodysplastic syndromes
|
May 2016
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry
|
Sep 2015
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series
|
Jan 2021
|
Annals of Hematology
|
aplastic anemia
|